Cite
Hybel TE, Vase MØ, Lauridsen KL, et al. CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leuk Lymphoma. 2022;1-5doi: 10.1080/10428194.2021.2023741.
Hybel, T. E., Vase, M. �. �., Lauridsen, K. L., Enemark, M. B., Møller, M. B., Pedersen, C., Pedersen, G., Hamilton-Dutoit, S., Obel, N., Schade Larsen, C., d'Amore, F., & Ludvigsen, M. (2022). CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leukemia & lymphoma, 1-5. https://doi.org/10.1080/10428194.2021.2023741
Hybel, Trine Engelbrecht, et al. "CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus." Leukemia & lymphoma vol. (2022): 1-5. doi: https://doi.org/10.1080/10428194.2021.2023741
Hybel TE, Vase MØ, Lauridsen KL, Enemark MB, Møller MB, Pedersen C, Pedersen G, Hamilton-Dutoit S, Obel N, Schade Larsen C, d'Amore F, Ludvigsen M. CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leuk Lymphoma. 2022 Jan 12;1-5. doi: 10.1080/10428194.2021.2023741. Epub 2022 Jan 12. PMID: 35019824.
Copy
Download .nbib